A B S T R A C T The concept of an abnormality of glutamine metabolism in primary gout was first proposed on the basis of isotope data: when ["N]glycine was administered to gouty subjects, there was disproportionately great enrichment of N-(3 + 9) of uric acid, which derive from the amide-N of glutamine. An unduly high concentration of "N in glutamine was postulated, and attributed to a hypothetical defect in catabolism of glutamine. Excess glutamine was proposed as the driving force of uric acid overproduction.
INTRODUCTION
Patients with primary gout and excessive uric acid excretion fed a test dose of ["N]glycine incorporate increased quantities of "N into urinary urate (1) (2) (3) (4) (5) . Although enrichment of all four nitrogen atoms of uric acid is excessive (5, 6) that of N-(3 + 9)' is dispro- ' In the studies of Gutman and Yu (6) , 1"N-9 was cal-portionately great, especially in flamboyant overexcretors of uric acid (6) . Since N-3 and N-9 of uric acid are derived from the amide-N of glutamine (7-9), Gutman and Yu (6, 10) proposed a defect in glutamine metabolism as the basis for excessive purine biosynthesis in primary gout. Since urinary ammonium, which arises principally from glutamine (11) (12) (13) (14) , is reduced in many gouty subjects (15) (16) (17) , they further postulated that the defect was a reduction of glutaminase activity (6, 10) . The recent finding of hyperglutamatemia in gout has shifted attention toward a possible defect of glutamate metabolism, resulting in diversion of glutarnic acid toward glutamine and purine biosynthesis (18) (19) (20) .
The original studies of "3N distribution in uric acid were performed before specific enzymic defects were recognized in gout, e.g., glucose 6-phosphatase deficiency (21, 22) , hypoxanthine-guanine phosphoribosyltransferase (PRT)' deficiencies of variable severity (23) (24) (25) (26) , and superactive a-5-phosphoribosyl-1-pyrophosphate (PP-ribose-P) synthetases (27) (28) (29) . In the last two rare subtypes of gout, the driving force of excessive purine biosynthesis is believed to be the demonstrably raised intracellular level of PP-ribose-P. Accordingly, we decided to determine whether preferential labeling of N-(3 + 9) after administration of labeled glycine also occurred in gouty subjects with accelerated purine production, based on known mechanisms unrelated to a defect of glutamine metabolism. The findings reported in this paper indicate that preferential labeling of N-(3 + 9) occurs in patients with accelerated purine production secondary to PRT deficiency or superactive PP-ribose-P synthetases, as well as in overproducers with idiopathic gout. Thus this labeling pattern appears to be a consequence of kinetic factors common to several different metabolic subtypes of gout, and not necessarily indicative of a defect of glutamine metabolism.
METHODS
['N]glycine, 95 .1 atom percent excess "N, used in experiments on subjects R. H., F. L., and S. G., was synthesized according to Schoenheimer and Ratner (30) . ["N]glycine, 95 atom per cent excess, used in experiments on subjects R. Jo. and 0. G., was purchased from Isomet Corp., Oakland, N. J. [1-"C] phenylacetic acid was purchased from New England Nuclear, Boston, Mass.
Uric acid was isolated from urine by adsorption on Darco-G60 (Darco Activated Carbon, Atlas Chemical Industries, Inc., Wilmington, Del.) at pH 4.2 overnight at 4'C, eluted with hot 0.1 N NaOH (31) , and repeatedly recrystallized from Li2CO3 solution (32) . All uric acid analyses were performed by the differential spectrophotometric 2 Abbreviations used in this paper: CoA-SH, reduced coenzyme A; formyl-GAM, a-formyl glycinamidineribonucleotide; formyl-GAR, a-formyl-GAR; 5-P,5-phosphate; GAR, glycinamideribonucleotide; PP-ribose-P, a-5-phosphoribosyl-1-pyrophosphate; PRA, jp-5-phosphoribosyl-1-amine; PRT, hypoxanthine-guanine phosphoribosyltransferase.
method (33) employing purified uricase purchased from Worthington Biochemical Corp., Freehold, N. J.
Uric acid samples were degraded by procedures which yield N-7 as glycine (34) and N-(1+3+9) (34) , N-(1 +7) (35) , N-(1+3) (36) , and N-(7+9) (36) as NH3. After alkalinization, the NH8 was collected in 1 N HCL. Hippuric acid was isolated according to Quick (37, 38) . Free urinary glycine was isolated as the dinitrophenyl (DNP) derivative according to Watts and Crawhall (39) . Urinary ammonia was recovered from fresh urine after alkalinization with saturated K2CO3 and collection in 1 N HCl. Phenylacetylglutamine was isolated from urine after the ingestion of [1-"C] phenylacetic acid by consecutive separations on cation and anion exchange resins as follows: An AG-50W X 8 H+ cation exchange resin (200-400 mesh) was converted to its Na+ form, placed in a chromatographic column (40 X 600 mm) and washed with citrate buffer (pH 3.42) according to Stein (40) . A urine sample of 50-100 ml was acidified to pH 2.3 and applied to the column, which was washed with successive 100-ml portions of citrate buffers of pH 2.5 and 2.9. Adsorbed compounds were eluted from the resin with citrate buffer of pH 3.42. Two radioactive peaks appeared, one before and one after the urea peak. The first of these represented unchanged ["C]-phenylacetic acid, and generally contained about 30% of the counts of the urine sample. The eluates comprising the second peak and containing phenylacetylglutamine (see below) were pooled and concentrated to a small volume by freeze-drying.
An AG-2 X 8 Cl-anion exchange resin (200400 mesh) was converted to its acetate form according to Hirs, Moore, and Stein (41) and placed in a 25 X 300-mm column.
The eluate containing phenylacetylglutamine was reduced to 50 ml vol, brought to pH 7.0, and applied to the resin. The resin was washed with 100 ml of 0.5 M acetic acid and then with successive 50-ml vols of acetic acid of increasing concentrations (1.0 M, 1.5 M, 2.0 M, etc.). The "C-labeled material appeared as a single peak is the 2.5 M acetic acid eluate and was collected in one sample of 100 ml. This fraction was taken to dryness by freeze-drying.
The solid material was extracted with and recrystallized from hot ethyl acetate. Both the crystalline material thus obtained, and authentic commercial phenylacetylglutamine, gave an Rr of 0.46 on silica gel thin-layer chromatography, employing butanol: acetic acid: water, 4: 1: 1, as solvent, and yielded equivalent amounts of ammonia and glutamic acid after hydrolysis in 3 N HCl at 100'C for 3 h (42).
The ammonia derived from the amide nitrogen of glutamine was separated from the hydrolysate, after alkalinization, by aeration into 1 N HCI. Residual glutamic acid was separated from any unhydrolyzed phenylacetylglutamine on Dowex 2-acetate resin (Dow Chemical Co., Midland, Mich.), prepared as described previously, and eluted with 0.5 N acetic acid.
All compounds or fractions not already in the form *of ammonia were digested by the micro-Kjeldahl method and steam-distilled to collect the ammonia.
Samples were prepared for '5N analysis according to Rittenberg (43) (1) 15(N-9)a = 2[15N(7 + 9) - [N-7] (2)
Although agreement of values of 15(N-9 
Sutbjects. Summary data on the subjects of this study are presented in Table I . The data on control subject R. H. were acquired during an earlier study (30 (27, 28) . T. B. was extensively studied at the N.I.H. and has been the subject of several reports (24, (47) (48) (49) . At the time of the study reported herein he was suspected of having a mutant PP-ribose-P amidotransferase with altered control features (47) . More larged miscible pool and enhanced extrarenal disposal of urate may have obscured more decisive evidence for overproduction in this subject (7) . The three other gouty patients present unequivocal evidence for extraordinary overincorporation of "N and excessive excretion and flamboyant overproduction of uric acid. Intramolecular distribution of "N in uric acid. Analytical value for "N in uric acid and N-7, and calculated values for "N in N-1 and N-(3 + 9) are given in Table   II , together with the percent of total "N in the various N atoms of each sample.
In Fig. 2 These data confirm those of Gutman and Yu (6) (4, 6) , that excessive incorporation of ['5N]glycine into uric acid in gout is not a reflection of abnormal enrichment or turnover of hepatic glycine, but rather that it is indicative of the utilization of a larger than normal fraction of the glycine turnover for purine biosynthesis per unit time (1) . Even in the most extraordinary overincorporators this fraction is less than 1%/day; hence it is not surprising that increased rates of purine biosynthesis do not produce detectable changes in the kinetics of turnover of the glycine pool.
In one subject (R. Jo.) free urinary glycine was isolated as DNP-glycine in order to determine how accurately the '5N enrichment of hippurate reflects that of glycine itself. The data are plotted in Fig. 4 . The 'N values of hippurate fall about 20% below those of free glycine at any point in time, but the curves are otherwise essentially identical.6 2V enrichment and turnover of the metabolic glutamine pool(s). Gutman and Yu (6) originally proposed that the disproportionately great enrichment of N-(3 + 9) in gouty subjects was attributable to "glutamine amide nitrogen containing an unduly high concentration of N`5." To evaluate this possibility we have sampled body glutamine by the periodic administration of phenylacetic acid. This approach is analogous to sampling of glycine by administration of benzoic acid (38) or of PP-ribose-P by administration of imidazoleacetic acid (53) .
Phenylacetylglutamine is a normal constituent of human urine. Fasting adult subjects excrete 250-500 mg/ day, and these quantities represent approximately 50% of conjugated glutamine of urine (40) . Excretion of phenylacetylglutamine is increased after ingestion of phenylacetic acid (54) and in patients with phenylketonuria who produce increased quantities of phenylacetic acid (40, 55, 56) . The reactions concerned have been defined by Mloldave and Meister (57, 58) in human liver mitochondria:
Phenylacetic acid + ATP =± Phenylacetyl-AMIP + PPi, (10) from the inverse design matrix defined by a Taylor expansion (51) of the nonlinear model and the estimated error variance. Unweighted analysis was selected because measurement errors in the mass spectrometer are constants, approximating +0.003 atom percent excess (52) . A minimum of three exponential functions is required to describe the data presented in Figs. 3 and 5 .
C Calculation of the size of the first glycine metabolic pool from the C. value of glycine, assumed to be 20% greater than the C. value of hippurate (see Fig. 3 ) gives an average value of 80.8 mg/kg in these five subjects, com- Phenylacetyl-CoA + L-glutamine = Phenylacetylglutamine + CoA-SH. (12) Preliminary studies were conducted in three normal controls and four normal excretor patients with idiopathic gout, in order to determine the rate of formation and excretion of phenylacetylglutamine. After oral administration of 1 g of [1-14C]phenylacetic acid (2-ACi 4C/g), from 66 to 70% of the administered '4C was excreted in urine in 3 h, and more than 96% in 12 h. About 70% of the '4C in the 3-h sample was in the form of phenylacetylglutamine. The rates of excretion of ["C]phenylacetylglutamine were the same in control and gouty subjects. The periodic oral administration of 1 g of phenylacetic acid was therefore employed to sample what is presunmably chiefly the hepatic glutamine pool. Urinary phenylacetylglutanmine was isolaated serially from one control (F. L.) and three gouty subjects (S. G., R. J., and 0. G.). These four subjects span a four-fold range of urinary uric acid excretion and a 25-fold range of ["'N]glycine incorporation values (Table I) . Immediately after administration of ['5N]glycine, the enrichment of urinary phenylacetylglutamine was very low. It rose to a maximum at about 3 h (see below) and then declined rapidly. The declining limbs of the enrichment curves are plotted in Fig. 5 . As in the case of labeling of urinary hippurate, the enrichment values from a single polyexponential dieaway curve, in which enrichment in the four subjects studied appears to be indistinguishable.
We conclude that the excessive incorporation of "5N into N-(3 + 9) of uric acid in gouty overproducers is not a reflection of abnormal enrichment or turnover of hepatic glutamine, but that (as in the case of glycine) l0o0 R.Jo. it is indicative of the utilization of a larger than normal fraction of the precursor glutamine pool for purine biosynthesis per unit time.
Precursor-product relationships. After the experimental labeling of a precursor pool, the concentration of isotope declines progressively as labeled molecules are replaced by newly synthesized unlabeled compound. The isotope concentration of each successive product of an unbranched pathway will achieve a maximal value when its enrichment equals that of its immediate precursor (59) . Fig. 1 Comparison of labeling of N-3 and N-9. The results presented thus far favor a kinetic explanation of the observed enhancement of labeling of N-(3 + 9) in gouty overproducers, which is independent of the nature of the specific metabolic abnormality that initiates purine overproduction.' However, Reem (65) has suggested an 'A computer model has been constructed simulating the kinetics of the reaction sequence of Fig. 8 . The isotopic enrichment of glycine is represented by the equation for the polyexponential die-away curve of hippurate shown in Fig.  3 . That of the amide-N of glutamine is represented by a first-order product curve derived from the enrichment of phenylacetylglutamine, which starts at zero, reaches a maximum at 3 h, and thereafter closely approximates the dieaway curve of Fig. 5 . The model also includes an arbitrary convention which accelerates a late reaction of the sequence (IMP --hypoxanthine) as a higher power function of [PP-ribose-P], in order to achieve a ratio of > 1 in the expression (increase in rate of synthesis of 6-phosphoribosylamine)/(increase of product pool size). With this model it is possible to show that an increase in concentration of PP-ribose-P will lead to a substantial increase in the ratio 5N-3/5N-7, or 1"N-(3 + 9)/'5N-(3 + 9 + 7) within the first few hours after administration of [1"N] glycine. Similar results are obtained if increased synthesis of uric acid is alternative explanation based upon a second pathway for synthesis of phosphoribosylamine that utilizes ammonia and ribose 5-phosphate, rather than glutamine and PP-ribose-P. The ribose 5-phosphate aminotransferase pathway (66) could theoretically lead to excessive incorporation of "5N selectively into N-9 of uric acid, if abnormally active in gout.8 Accordingly, calculations were made of the relative labeling of N-3 and N-9.
In previous studies, the percentage of '5N in either N-3 or N-9 was considered to be half the percentage calculated in N (3 + 9) (38), or conversely, the percentage in N-(3 + 9) was assumed to be twice that calculated in N-9 (6). This practice rests upon several assumptions: first, that N-3 and N-9 are equivalently labeled by virtue of an exclusive common origin from the amide-N of glutamine (7) (8) (9) ; second, that both N-3 and N-9 come from the same glutamine pool, or from different pools identically labeled; third, that there are no exchange reactions involving the N-atom of either intermediate; and fourth, that there are no pools of intermediates between PRA (which contains the eventual N-9 atom) and formyl-GAM (which contains the eventual N-3 atom) of sufficient magnitude to dilute N-9 relative to N-3.
We have reexamined the question of equivalence of labeling of N-9 and N-3 in four subjects, including one control (F. L.), one patient with idiopathic gout (S. G.), predicated upon an increase in concentration of glutamine, or an increase in activity of the amidotransferase, provided that compensatory expansion of product pool size is prevented by some convention in each case. This model will be presented in detail in another publication (Starmer, C.
F., 0. Sperling, and J. B. Wyngaarden. A kinetic model for uric acid labeling in primary gout. In preparation.) 8 However, in order for an alternative pathway of synthesis of p-5-phosphoribosyl-1-amine (PRA) to result in greater enrichment of N-9 in patients with excessive rates of purine biosynthesis, and in an increase in the labeling ratio under consideration, the condition that expansion of product pools not cancel out effects of increased rates of synthesis must also be met. . Values for N-9 and N-3 were calculated as described above (Eq. 2 and 7). Fig. 9 shows that, contrary to long-held assumptions, enrichments of N-9 and N-3 are not equivalent. During the first 2 days there is a tendency for N-9 to be more highly enriched than N-3, whereas at later times the reverse is observed. The mean of all values of the ratio NN-9/'5N-3 on day 1 is 1.24, on day 2 is 1.42, on day 3 is 0.86, and on days 4 through 18 is 0.59. Fig. 10 shows that the ratio "5N-9/ 5N-uric acid is fairly constant in any given subject.9
By contrast (Fig. 11 ) the ratio '5N-3/'5N-uric acid appears to increase with time in all subjects studied. Note that excessive incorporation of '5N into uric acid in the overexcretor gouty subjects is not associated with a selective increase of enrichment of N-9 or N-3 relative to the other member of this pair (Fig. 9) . Despite the scatter of points, the values of the ratio ':N-9/5N-3 in the four subjects appear to overlap on any given day. In Figs. 10 and 11, T. B., the most dramatic gouty overproducer included in this phase of the study, shows the highest fractional enrichment of both N-3 and N-9. Thus a selectively excessive incorporation of '5N into N-9 is not the explanation of the elevated '5N-(3 + 9) /[5N]
uric acid ratios observed in gouty overproducers.
Sequence of enrichment of urinary products. The study on the remarkable overproducer, 0. G., offered an opportunity to observe the sequences of enrichments of various urinary constituents (Fig. 12) . The earliest p)eaks were found in hippurate and amnionia at 1.5 h, in 'This may be a variable feature. Whereas this ratio was also fairly constant with time in five subjects (three control, two gouty) of Gutman and Yu (6) it rose in four others (gouty subjects), as well as in one control studied by Shemin and Rittenberg (34) . agreement with findings by Wu and Bishop (67) in a normal subject. Maximal enrichment of the amide-N of phenylacetylglutamine occurred at 3 h. Peak enrichment of N-7 was found at 3 h, and N-(3 + 9) at 5.5 h. Glycine, the immediate precursor of hippurate and of N-7, had presumably reached its enrichment maximum somewhat earlier, perhaps at about 1 h (67). Glutamine probably reached its maximal enrichment sometime past 1.5 h, based on the time of peak enrichment of urinary anmmonia, and the presumed operation of the glutamine synthetase reaction (see below). The source of the urinary ammonia, highly labeled so early, is probably glycine itself, by deamination in liver and kidney catalyzed by glycine decarboxylase (68) or D-amino acid oxidase (69) . In the 1st h, the enrichment of urinary ammonia is nearly 50 times greater than that of the amide-N of phenylacetylglutamine, whereas that of hippurate is less than twice that of ammonia (Fig. 12) . Enrichment values of ammonia declined to equal those of the amide-N of phenylacetylglutamine in the 7-12-h sample, and the two values were much the same thereafter throughout the 7 days of the study. The results in control subject F. L. and gouty subject S. G. were similar, but in PRTdeficient subject R. Jo., enrichment values of NH3 averaged 24% greater than those of the amide-N (Table  III) . Ammonia is thus a plausible candidate for the source of the excessive enrichment of N-9 with respect to N-3 on days 1 and 2 (see Discussion). However, preferential entry of 'N into N-(3 + 9) is not observed when '5NH4Cl itself is fed to gouty subjects (5) . In this circumstance one would anticipate nearly simultaneous, rather than sequential, labeling of glycine and the amide-N of glutamine, and a fixed ratio, 'N-3/1N-7, regardless of rate of purine biosynthesis. Glutamate + NH3 + ATP Glutamine + ADP + Pi, (13) 2 Glutamate + NADP = Glutamine + a-Ketoglutarate + NADPH. (14) Glutamine synthesized in the former reaction should contain more 'N in the amide-than the amino-N, whereas glutamine synthesized in the latter reaction should contain equivalently labeled N atoms. Measurements of 15N contents of the two nitrogens of glutamine were made on 30 samples from three subjects of the present study (Table III) 1.5 or greater in each subject, and passed through a maximum on the 3rd-5th day. These results indicate that the glutamine synthetase reaction is the more important reaction for synthesis of glutamine in man, and are consistent with the failure to demonstrate the glutamate synthetase reaction in animal tissues thus far (71) . DISCUSSION In this paper we demonstrate the disproportionately increased labeling of N-(3 + 9) of uric acid from ['5N]-glycine in patients with rare subtypes of primary gout attributable to specific enzymatic defects unrelated to glutamine metabolism. We postulate that the changes in "5N-(3 + 9)/['N]uric acid ratios observed with accelerated purine production are related to: first, different time courses of enrichment of precursor glycine and glutamine pools, labeled consecutively rather than simultaneously and with different turnover characteristics; and second, kinetic factors which reflect the differences of early enrichment patterns of these precursor pools most strikingly in the most rapid producers, irrespective of the precise molecular cause of purine overproduction.
The first specific step of purine biosynthesis de novo involves the following reaction catalyzed by glutamine phosphoribosylpyrophosphate amidotransferase (72, 73) : a-PP-ribose-P + glutamine Mg2+ + H20
6-phosphoribosylarnine + glutamic acid + PP'i. (15) lThis reaction appears to be the slow and rate-controlling step of the purine biosynthetic pathway (74) . The amidotransferase is subject to synergistic allosteric feedback inhibition by adenyl and guanyl ribonucleotides (73, 75) . The molecular basis of this control mechanism has now been elucidated. Purine ribonucleotides convert the human enzyme, which in its active form has a molecular weight of 133,000, to a larger form that has a molecular weight of 270,000 and is enzymatically inactive. PP-ribose-P reconverts the larger form of the enzyme to the smaller form and stabilizes it in that configuration. Glutamine has no effect upon this associationdissociation reaction (76) .
Increases in rates of purine production could in theory result from increased concentrations of the substrates PP-ribose-P or glutamine, increased activity of the amidotransferase, or decreased availability or nonoptimal ratios of feedback inhibitors (50, 73) .
The Km value of human amidotransferase for PP-ribose-P is 0.25 mMl (75) . The fibroblasts) (77) (78) (79) . Thus the intracellular concentrations of PP-ribose-P may be in the low ranges of the substrate-velocity curves, and factors that affect their intracellular, perhaps chiefly intrahepatic, concentrations will have a corresponding influence upon purine biosynthesis de novo. The amidotransferase reaction displays sigmoidal kinetics with respect to PP-ribose-P in the presence of ntucleotide regulators such as AMP and GMP (75) . Small increases in concentrations of PP-ribose-P may therefore affect purine biosynthesis disproportionately. Indeed, in isolated systems such as Ehrlich ascites cells (80) or cultured human fibroblasts (77, 81) , manipulations of the concentrations of PP-ribose-P profoundly affect the rate of the first steps of purine biosynthesis. Concentration values of PP-ribose-P are normal in erythrocytes and cultured fibroblasts of patients with idiopathic gout whose urate excretion values are in the normal range (75, 77, 79, 82) . These subjects are representative of 70-75% of the gouty population (4, 44).
However, PP-ribose-P values are significantly elevated in erythrocytes of patients with partial (77) or virtually complete (77, 78) deficiencies of PRT activity, and in patients with superactive PP-ribose-P synthetases (28, 29) , as well as in some gouty patients with idiopathic gout and excessive urate excretion values (47, 83, 84) .
In an earlier study from this laboratory on nine subjects with idiopathic gout, an increased labeling of the ribose moiety of urinary imidazoleacetic acid ribonucleoside (which is derived from PP-ribose-P) was found ill three overproducers after administration of [U-14C]glucose, but not in six normal excretors (53) . These data strongly suggested overproduction of PP-ribose-P from glucose in the three gouty overproducer subjects. The nature of the metabolic defect in these patients has not been clarified except that one (H. H.) had normal erythrocyte PRT activity."0 Taken altogether, available data suggest that increased concentration values of PP-ribose-P may drive purine biosynthesis excessively in some patients with gout. This mechanism is strongly supported by analytical data ill two rare subtypes of gout, associated with PRT deficiency or increased PP-ribose-P synthetase deficiency, which together, however, represent only about 2% of the gouty population (26, 27, 85) . This mechanism has also been suggested as the basis of purine overproduction in Gierke's disease (22) , which is rare, as well as in hyperuricemia associated with variant forms of glutathione reductase characterized by increased enzymatic activity (86) , which according to Long (86, 87) glutamine PP-ribose-P amidotransferase reaction are such that small increases of PP-ribose-P concentration could account for the lesser degrees of purine overproduction in patients with idiopathic gout, although at present no data exist in direct support of this hypothesis.
The critical values to be determined in patients with all forms of gout are those of PP-ribose-P concentration or production rate in liver, on which no data are as vet available.
Plasma levels of glutamine are 0.5-0.7 mAI in both normal and gouty subjects (18, 19, 88) . These values are below the glutamine Km value of 1.6 mM for human placental (75) or lymphoblast (89) amidotransferase.
The rate of purine biosynthesis in cultured fibroblasts can be reduced by glutamine starvation (90) , for these cells do not have the highly developed enzymatic machinery for synthesis of glutamine present in liver. We have been unable to find data in the literature on concentrations of glutamine in human liver. However, values of free glutamine in the protein-free extracts of liver of fed rats, whether determined after acid (91) The Km for glutamine of PP-ribose-P amidotransferase of rat liver is < 1 mM (94) . Therefore, in the fed rat this enzyme of the purine pathway may be nearly satuirated with respect to glutamine.
If the human enzyme is not saturated with glutamine, variations in glutamine concentrations would be expected to affect the rate of purine biosynthesis, although less exquisitely than variations in concentrations of PPribose-P. The kinetics of the amidotransferase reaction are hyperbolic with respect to glutamine at all levels of PP-ribose-P, in the presence or absence of nucleotide inhibitors (75, 94) . Purine ribonucleotide inhibition is noncompetitive with respect to glutamine (75, 94) and glutamine does not reverse the association of amidotransferase subunits caused by ribonucleotides (76) .
The three elements of the hypothesis of abnormal gltutamine metabolism in primary (idiopathic) gout are: first, disproportionate labeling of N-(3 + 9) in urate overproducers after ingestion of ['3N]glycine (6, 10) ; second, reduced production of urinary NH3 at a given acid load (15) (16) (17) ; and third, hyperglutamatemia (18, 19) that appears to be independent of dietary protein level (18) . The disproportionate labeling of N-(3 + 9) has now been shown to be a general feature of accelerated purine biosynthesis, and therefore this finding does not specifically favor a defect of glutamine metabolism in primary gout. The reduced production of urinary NH3 in gout was initially attributed to a defect in glutaminase activity (6, 10), but this postulated mechanism appears to have been excluded by normal renal glutaminase as-say values in vitro in four gouty subjects (95) . However, Pitts (96) has cited possible disparities between glutaminase activities as assessed in vitro and in vivo, and a "functional deficit" of glutaminase activity in gout has been suggested by Gutman and Yu (15) . The hyperglutamatemia (18, 19) has led to the proposal that surplus glutamate may drive purine biosynthesis via glutamine in certain subjects. However, even if there should be a defect of glutamate or of glutamine metabolism, it is not clear how such metabolic errors could account for the isotopic data, for an increase in concentration of free glutamine in liver would result in greater dilution of newly synthesized labeled glutamine and reduced rather than increased labeling of N-3 and N-9 relative to N-7 or total uric acid.
The observation that enrichment patterns calculated for N-9 and N-3 followed different time-courses was unanticipated. It had been assumed that N-9 and N-3 were equivalent by virtue of a common origin in the amide-N of glutamine. The nonequivalence cannot be explained by progressive dilution of "N in intermediates along the pathway of purine biosynthesis, for such factors would dilute N-3 with respect to N-9 in all samples.
One theoretical basis for nonequivalence is different glutamine pools as precursors of the two N-atoms. This appears unlikely. All enz)ymes of purine biosynthesis reside in the cytosol, apparently in a large multienzyme coml)lex capable of total synthesis of IMP from low molecular weight substrates (97) . Exchange of NH3 with the amino group of plhosphoribosylanline is also unlikely: the amidotransferase reaction is irreversible (72, 73) .
A second reaction introducing highly enriched N H3 into N-9 initially and NH3 less highly labeled than the amide-N of glutamine some days later could explain the findings, and is consistent with the observed time-courses of enrichment of NH3 and of the amide-N of glutaminie. Both PP-ribose-P amidotransferase (72) (100) , its potential biological significance has been doubted. In fact, pur F mutants of E. coli, which lack any activity of glutamine-PPribose-P amidotransferase, are strict purine auxotrophs (101) , even though they contain normal activity of ribose 5-P aminotransferase." Doubt has also been expressed that this reaction functions in Ehrlich ascites " Gots, J. May, 1972. Personal communication.
cells (102) . Nevertheless, suggestive evidence for this pathway exists in other systems (103) (104) (105) , and Reeni (65, 66) has shown that tissue extract fractions that catalyze this reaction contain no glutamine PP-ribose-P amidotransferase activity. The '5N-9/'5N-3 ratios of the present study could perhaps be explained by a direct reaction between ammonia and ribose 5-P, occurring either enzymatically or chemically, giving rise to phosphoribosylamiine. The limited data available (Fig. 9) do not suggest that the activity of this putative alternative pathway is selectively increased in gouty subjects.
In summary, the increased fractional labeling of N-3 and N-9 of uric acid in gouty overproducers fed [ 
